The Immune Response to Schistosome Antigens in Formerly Infected Travelers

Darius Soonawala,* Jan-Willem H. J. Geerts, Marissa de Mos, Maria Yazdanbakhsh, and Leo G. Visser

Department of Infectious Diseases and Tropical Medicine, Leiden University Medical Center, Leiden, The Netherlands; Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands

Abstract. We investigated the type and strength of the immune response to schistosome antigens in a group of 20 Dutch travelers who had been infected with Schistosoma spp. during a group visit to Mali in 1991 and 8 non-infected controls. At the time, 9 had Katayama syndrome (KS), and 11 remained asymptomatic. All had been treated with praziquantel. Eight years later, serology remained positive in all 20 formerly infected travelers. The lymphocyte proliferative responses and cytokine responses (interleukin 13 [IL-13], IL-10, and interferon [IFN-γ]) responses to soluble egg antigens and the IL-13, IL-10, and IL-5 response to adult worm antigen) were stronger in the travelers than in the controls and tended to be stronger in those with KS compared with those who had remained asymptomatic. In conclusion, Schistosoma infection induced a memory immune response, and people who experienced KS tended to have a stronger immune response to schistosome antigens than their asymptomatic counterparts.

INTRODUCTION

Most of the information on the immunopathology of schistosomiasis is derived from murine models.1–4 Studies in humans have mainly focused on chronic infections seen in endemic areas.5 The acute response known as Katayama syndrome is thought to occur in non-immune hosts only.6 Prior exposure to antigens in utero7–12 or infection early as opposed to late in life is believed to account for this difference in symptoms between persons living in an endemic area and non-immune hosts.

Several studies have analyzed the acute response after a primary Schistosoma infection.13–16 The symptoms in non-immune hosts vary widely.17,18 Some non-immune subjects develop Katayama syndrome, whereas others remain (virtually) asymptomatic. The reason for this difference remains unknown.19,20 Immunologically, eosinophilia and circulating immune complexes have been associated with acute schistosomiasis.21–23 and it has been suggested that the cause of Katayama syndrome is a systemic hyperreactive immune response to migrating schistosomula.21

Schistosomiasis in travelers can be considered an experiment of nature with a defined exposure in time, a non-immune host, low infection intensity, and lack of coinfection or reinfec-

MATERIALS AND METHODS

Subjects. Subjects were recruited from an single episode of schistosomiasis that occurred among 28 Dutch travelers who had been infected during a swim in fresh water pools in the Dogon area in Mali in 1991.17 At the time, 15 had developed Katayama syndrome, which was defined as occurrence of two or more of the following symptoms: fever, sweating, abdominal pain, myalgia, arthralgia, diarrhea, dry cough, weight loss, hepatomegaly, splenomegaly, urticaria, or swollen eyelids.

Treatment with praziquantel had resulted in parasitological cure in all travelers. In 1999, when this current study was performed, 21 of the initial 28 subjects could be contacted for collection of venous blood. To exclude actual Schistosoma infection, stool and urine samples of all 21 subjects were screened for schistosome eggs by sedimentation selective filtration methods.21 In short, washed stool samples were sifted first through a sieve with 106-μm pores and then through a sieve with 53-μm pores. Five wet smears of each sample were searched for schistosome eggs. Urine samples were centrifuged for 10 minutes at 2,500 rpm, and the entire sediment was examined. Stool and urine tests were performed two times on separate occasions before considered negative. As controls, eight Dutch individuals who had never traveled to Schistosoma-endemic regions provided venous blood.

Serology. Antibodies to S. mansoni-derived somatic antigens (adult worm antigen [AWA]) were assessed by an indirect immunofluorescence assay (IFA) for the detection of immunoglobulin M (IgM) antibodies using paraffin sections of adult male Schistosoma mansoni with Rossmann fixative. IgG antibodies to egg antigens (soluble egg antigens [SEA]) were assessed by enzyme-linked immunosorbent assay (ELISA).21,22

Antigens. AWA and SEA were prepared from 1.5 to 2 g S. mansoni adult worms and eggs, respectively. After homogenizing in an all-glass homogenizer in a 0.035 M phosphate buffered saline (PBS), pH 7.8, at 0°C, the homogenate was transferred to a glass tube and sonicated for 3 minutes at level 7 in a sonicator (Branson Sonic Power Company, Sonicator B-12 power supply and converter, Danbury, CT) at 0°C. Next, the homogenate was centrifuged for 20 minutes at 25,000 rpm at 4°C, and the supernatant was collected. The pellet was homogenized again, and the supernatant was collected for a second time. The first and second collected supernatants were pooled together and dialyzed against distilled water at 4°C. During this procedure, the water was changed two times. The dialyzed supernatant was lyophilized and stored at 4°C. The protein content of the antigen fractions in the dialyzed supernatants was determined by a bichronic acid method (BCA; Pierce III, Rockford, IL) against standard series from solution of bovine serum albumin. Finally, the antigens were dissolved in IScoves medium at a protein concentration of 20 μg/mL.
Purified protein derivative (PPD) of *Mycobacterium tuberculosis* (Statens Serum Institute, Copenhagen, Denmark) was diluted in Iscoves medium (Gibco, Paisley, Scotland) to a concentration of 20 μL derivative per 1 mL. Tetanus toxoid (TT; RIVM, Bilthoven, The Netherlands) was diluted to a concentration of 1.5Lf (flocculation units) per 1 mL of Iscoves medium. Phytohaemaglutin (PHA; Murex Biotech Ltd., United Kingdom) was diluted to a concentration of 4 μg per 1 mL of Iscoves medium.

**Cellular stimulation assay.** Peripheral blood mononuclear cells (PBMC) were isolated from heparinized venous blood by Ficoll-Hypaque density gradient centrifugation. Cells were frozen in Roswell Park Memorial Institute (RPMI; Gibco) supplemented with 2 mM/L glutamine, 1 mM/L pyruvate, 20% (vol/vol) pooled human serum, and 10% (vol/vol) dimethyl sulfoxide (DMSO; Merck, Darmstadt, Germany). Viability after thawing was determined by trypsin blue dye exclusion. Only cell suspensions with at least 90% viability were used. For the proliferation assay, PBMC (10^6 cells per well) were incubated in flat-bottomed microtiter wells (NUNC maxisorb; Life Technologies, Breda, The Netherlands) in 100 μL of Iscoves medium (Gibco) supplemented with 10% (vol/vol) pooled human serum, 2 mM/L glutamine, 1 mM/L pyruvate, 100 U/mL penicillin, and 100 μg/mL streptomycin in triplicate at 37°C in humidified air containing 7.5% CO₂ in the presence or absence of antigen.

For the determination of cytokine production, PBMC (10^6 cells per well) were incubated in round-bottomed microtiter wells (NUNC maxisorb) in the presence or absence of antigen in 100 μL of Iscoves medium (Gibco) supplemented with 5% (vol/vol) fetal calf serum, 2 mM/L glutamine, 1 mM/L pyruvate, 100 U/mL penicillin, and 100 μg/mL streptomycin in triplicate at 37°C in humidified air containing 7.5% CO₂. After the indicated time, the supernatants were collected, and they were immediately frozen and stored at −20°C for subsequent determination of cytokine production. The final concentrations of antigens used were: AWA, 10 μg/mL; SEA, 10 μg/mL; PHA, 2 μg/mL; PPD, 10 μg/mL; TT, 0.75 Lf.

**Proliferation assay.** The lymphoproliferative responses to antigen stimulation (AWA and SEA) were determined by adding 1 μCu of [³H]-thymidine, uptake was measured by a scintillation counter. Mitogenic stimulus PHA were determined by adding 1 μCu of [³H]-thymidine, uptake was measured by a scintillation counter. Values were expressed as stimulation index (SI). SI equals the geometric mean of (mean counts per minute [cpm] of the stimulated culture)(mean cpm of the unstimulated cultures).

**Cytokine production.** Supernatants were collected for determination of interleukin 10 (IL-10) and IL-13 on day 3 and interferon (IFN-γ) and IL-5 responses on day 5. Cytokines were measured by use of ELISA using specific capture and detection monoclonal antibodies (IFN-γ, IL-13, and IL-10, Pelikine Compact ELISA kit; Central Laboratory of Bloodtransfusion, Leiden, The Netherlands and IL-5; BD; Pharmingen; Franklin Lakes, NJ). The detection limits of the assays were 3 pg of IFN-γ/mL, 3 pg of IL-10/mL, 3 pg of IL-5/mL, and 3 pg of IL-13/mL. The upper limit was 30,000 pg/mL, and any value above was defined as 30,000 pg/mL. Detectable values in unstimulated cultures were subtracted from the value in stimulated cultures. When this difference was negative, the value of produced cytokine after stimulation was defined as 1.5 pg/mL. Cytokine responses could not be determined in all subjects because of technical problems with the assay and the limited amount of blood.

**Statistical analysis.** Differences between responses were tested with the non-parametric Mann–Whitney test. Statistical significance was defined as a P value < 0.05. No correction was made for multiple testing.

**RESULTS**

**Study subjects’ infection and clinical status.** Twenty-one subjects who had been treated for schistosomiasis in 1991 volunteered to participate in the current study. At the time of diagnosis in 1991, all subjects had positive schistosome serology, and 15 subjects (71%) had eggs in the feces and/or urine. In 1999, renewed microscopic examination of stool and urine was performed twice on separate occasions in all subjects. Schistosome eggs were found in the stool of only 1 traveler. This patient was treated with praziquantel and excluded from further analysis. Twenty travelers were included in the present analysis, 9 who had suffered Katayama syndrome in 1991 and 11 who were asymptomatic. Of these 20 subjects, 14 (70%) had eggs in the feces and/or urine in 1991. Twelve of these subjects (12/14; 86%) had been infected with *S. mansoni*, often as part of a mixed infection with *S. haematobium* (Table 1).

**Serologic response to AWA and SEA.** Serum antibodies to AWA and SEA were determined in all travelers at 12.6 (±2.5) weeks after fresh water exposure and in 1999. Median IgG anti-AWA and SEA were determined in all travelers at 12.6 (±2.5) weeks after fresh water exposure in 1991 and 55.7 (±15) weeks and 8 years after treatment. Eight years after treatment, none of the travelers had reverted to negative serology for both AWA and SEA, although IgM anti-AWA titers had decreased. Median IgM anti-AWA titers were: 1:1,024 (IQR = 1:1,024–1:2,048) at 12.6 weeks, 1:1,024 (IQR = 1:512–1:1,024) at 55.7 weeks, and 1:362 (IQR = 1:128–1:861) at 8 years. Median IgG anti-SEA titers were: 1:128 (IQR = 1:64–1:256) at 12.6 weeks, 1:256 (IQR = 1:76–1:256) at 55.7 weeks, and 1:128 (IQR = 1:76–1:256) at 8 years. At all three time points, median antibody levels did not differ significantly between the group with Katayama syndrome and the group that had remained asymptomatic.

**Lymphocyte proliferative response.** The lymphoproliferative response could be determined for 18 of 20 travelers. A lymphoproliferative response was seen to both AWA and SEA, although IgM anti-AWA titers had decreased. Median IgM anti-AWA titers were: 1:1,024 (IQR = 1:1,024–1:2,048) at 12.6 weeks, 1:1,024 (IQR = 1:512–1:1,024) at 55.7 weeks, and 1:362 (IQR = 1:128–1:861) at 8 years. Median IgG anti-SEA titers were: 1:128 (IQR = 1:64–1:256) at 12.6 weeks, 1:256 (IQR = 1:76–1:256) at 55.7 weeks, and 1:128 (IQR = 1:76–1:256) at 8 years. At all three time points, median antibody levels did not differ significantly between the group with Katayama syndrome and the group that had remained asymptomatic.

**Table 1**

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>Katayama syndrome (N = 9)</th>
<th>No Katayama syndrome (N = 11)</th>
<th>Controls (no infection, N = 8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/female</td>
<td>4/5</td>
<td>4/7</td>
<td>5/3</td>
</tr>
<tr>
<td>Mean age in years</td>
<td>52.0</td>
<td>52.1</td>
<td>22</td>
</tr>
<tr>
<td>Number of subjects positive for <em>S. mansoni</em> spp. eggs in stool or urine in 1991</td>
<td>7 (78%)</td>
<td>7 (64%)</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>3 (33%)</td>
<td>1 (9%)</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>1 (11%)</td>
<td>1 (9%)</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>1 (9%)</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>2 (22%)</td>
<td>2 (18%)</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>2 (18%)</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>1 (11%)</td>
<td>1 (9%)</td>
<td>–</td>
</tr>
<tr>
<td>No eggs found</td>
<td>2 (22%)</td>
<td>4 (36%)</td>
<td>–</td>
</tr>
<tr>
<td>Number of subjects positive for <em>S. haematobium</em> spp. eggs in stool or urine in 1991</td>
<td>0</td>
<td>0</td>
<td>–</td>
</tr>
</tbody>
</table>
15 (mean = 25, standard error = 6) and in response to SEA was 10 (mean = 12, standard error = 3); the median SI in controls in response to both AWA and SEA was 1 (mean = 1, standard error = 1). Although the median responses were stronger in those who had experienced Katayama syndrome in the past (SI for AWA = 30, SI for SEA = 15) compared with those who had remained asymptomatic (SI for AWA = 9, SI for SEA = 7), these differences did not reach statistical significance (P values for the differences = 0.17 and 0.08, respectively) (Table 2).

Cytokine responses. In comparison to non-infected controls, travelers had higher levels of IL-5, IL-10, and IL-13 in response to AWA. In response to SEA, travelers showed higher production of IFN-γ, IL-10, and IL-13 (Figure 1). Travelers who had experienced Katayama syndrome in the past showed higher production of IL-13 (P = 0.03) in response to AWA and higher production of IL-13 (P = 0.009), IFN-γ (P = 0.004), and IL-5 (P = 0.06) in response to SEA compared with those who had been infected but remained asymptomatic (Figure 1). The IL-10 responses were similar in those with and without Katayama syndrome. Ten samples were taken at random and stimulated with TT and PPD. No differences in production of IL-5, IL-10, IL-13, and IFN-γ were seen between four travelers who had Katayama syndrome and six travelers who did not.

DISCUSSION

Eight years after treatment of schistosomiasis, positive serology persisted in all 20 travelers. There was also a specific lymphoproliferative response to schistosome antigens, which indicates that an acute schistosome infection in a naïve subject induces a memory response that lasts for at least 8 years. Long-lasting positive serology after treatment of schistosomiasis is consistent with previous reports. This may be caused by persisting egg antigens, providing a stimulus to the immune system even after worms are eliminated. However, worms have been known to survive in the human host for up to 31 years, and treatment has been known to fail. Egg secretion was the only method to establish whether an active infection was still present. Although we performed microscopic analysis two times, examining five wet smears per stool sample and the entire urine sediment on each occasion, we cannot exclude the possibility of persisting low-grade infection as a cause of long-lasting positive serology. Furthermore, the antibodies can be cross-reactive to antigens from other sources such as certain carbohydrates. Therefore, even without infection,
stimulation of antibody production may occur from time to time.

It is surprising that AWA induced IFN-γ production in the controls but no lymphocyte proliferation in the controls. High IFN-γ levels in controls have been reported before in response to AWA and SEA.6 It is possible that components of these antigenic mixtures bear pathogen-associated molecular patterns and react with pattern recognition receptors on immune cells, such as monocytes, B-lymphocytes, or natural killer (NK) cells. The IFN-γ response to AWA in uninfected subjects might be produced by NK cells, which can readily release IFN-γ in response to stimulation by pathogen-associated molecular patterns (PAMPs).20 We do not know if these PAMPs are schistosome-specific or caused by endotoxin contamination.

The data suggest that 8 years after treatment of schistosomiasis, those who had Katayama syndrome in the past had stronger or less well-regulated lymphoproliferative and cytokine responses to schistosome antigens compared with those who were infected but remained asymptomatic. However, most differences did not meet conventional levels for statistical significance. In addition, all stimulation assays were done with S. mansoni-derived antigens. We can not fully rule out that S. haemaobium- or S. intercalatum-infected subjects would react less with S. mansoni antigens. Studies conducted on Senegalese patients living in an endemic area with single S. haemaobium, single S. mansoni, or mixed S. haemaobium and S. mansoni infections indicated that the antigens are cross-reactive when it comes to cytokine production. In other words, there was no consistent pattern showing that S. haemaobium-infected subjects respond better to S. haemaobium antigen than S. mansoni antigen or vice versa (unpublished data).

Nevertheless, the percentage with proven infection among those who had Katayama syndrome, 17, 19 and the stronger IL-5 responses to schistosome antigens compared with their asymptomatic counterparts. This is in line with the idea that Katayama syndrome is caused by a hyperreactive immune response to migrating schistosomula or eggs. Why some do and others do not mount such a hyperreactive immune response remains unknown. Differences in the genetic background or the antigen load during the acute infection offer plausible but unproven explanations.

Received May 6, 2010. Accepted for publication October 7, 2010.

Acknowledgments: The authors thank Yvonne C. M. Kruize for her assistance in performing the laboratory analysis. The study protocol was approved by the Medical Ethics Committee of the Leiden University Medical Center (Protocol P42/99). Informed consent was obtained from all participants.

Financial support: There was no dedicated funding for this project.

Authors’ addresses: Darius Sooanawala, Jan-Willem H. J. Geerts, and Leo G. Visser, Department of Infectious Diseases and Tropical Medicine, Leiden University Medical Center, Leiden, The Netherlands, E-mails: d.soonawala@lumc.nl, geerts.jw@gmail.com, and l.g.visser@lumc.nl. Marissa de Mos, Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands, E-mail: m.vrolijk-demos@erasmusmc.nl. Maria Yazdanbakhsh, Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands, E-mail: m.yazdanbakhsh@lumc.nl.

REFERENCES